TRINITA’ project

Financed under the Cascade Calls of the NODES Program, supported by the Ministry of University and Research (MUR) through PNRR funds. It falls under the MUR – M4C2 – Investment 1.5 Notice titled “Innovation Ecosystems,” which is part of the PNRR funded by the European Union – NextGenerationEU

Grant agreement Code No. ECS00000036

Progetto TRINITA’

Finanziato nell’ambito dei Bandi a Cascata del Programma NODES, sostenuto dal MUR sui fondi PNRR MUR – M4C2 – Investimento 1.5 Avviso “Ecosistemi dell’Innovazione”, nell’ambito del PNRR finanziato dall’Unione europea – NextGenerationEU

Grant agreement Code No. ECS00000036

Project Name: Trinità
Funding Line: Line 5 of the PNRR
Lead Organization: Dompé Farmaceutici

Project Objectives

The Trinità project aims to:

• Develop innovative therapeutic solutions.
• Implement cutting-edge medical technologies.
• Promote advanced scientific research.

ViroStatics’ Role

ViroStatics is involved in various aspects of the project, contributing its expertise in biotechnological research and the development of new therapeutic treatments. The company is committed to:

• Collaborating closely with Dompé Farmaceutici to achieve the project’s goals.
• Utilizing PNRR funding to accelerate research progress.
• Contributing to the creation of innovative medical solutions that can improve patients’ quality of life.

Importance of PNRR Funding

The National Recovery and Resilience Plan represents a unique opportunity to support research and development projects in Italy. The funding received for the Trinità project enables ViroStatics to:

• Expand its research capabilities.
• Experiment with new technologies and methodologies.
• Collaborate with excellence partners like Dompé Farmaceutici.